Introduction {#Sec1}
============

Advances in therapy for malignancies, autoimmune disorders, and end-stage organ diseases have lead to improved survival, but also to an increase in the number of immunosuppressed patients (ISP). These patients are at risk for opportunistic infections and also for community-acquired infections, such as respiratory virus infections, with considerable related morbidity and mortality \[[@CR1]--[@CR3]\].

In April 2009, a novel influenza A (H1N1) virus was identified and propragated throughout the world \[[@CR4]\]. Clinical findings of influenza A 2009 (H1N1) virus infection were similar to those of seasonal influenza, with many patients having mild illness \[[@CR5]\]. However, severe cases occurred, with over 18,000 patients dying throughout the world. Among hospitalized patients with severe influenza A 2009 (H1N1), 15--20% were immunosuppressed \[[@CR6], [@CR7]\]. Given the behavior of seasonal flu in ISP, a higher number of influenza-related complications in this population could be expected \[[@CR3], [@CR6], [@CR8], [@CR9]\]. However, data regarding clinical features and outcomes in non-human immunodeficiency virus (HIV) ISP are needed. The objective of this investigation was to prospectively characterize the clinical manifestations and outcomes of influenza A 2009 (H1N1) virus infection in ISP.

Methods {#Sec2}
=======

Setting, study subjects, and study design {#Sec3}
-----------------------------------------

This prospective cohorts observational study was conducted at 13 teaching hospitals belonging to the Spanish Network for Research in Infectious Diseases (REIPI). All patients older than 16 years of age admitted to the hospital with confirmed pandemic influenza A 2009 (H1N1) virus infection from June 12, 2009 to November 11, 2009 were included. Cases were detected on a daily basis by reviewing the microbiological reports. A confirmed case was defined in the presence of influenza-like illness with laboratory-confirmed pandemic influenza A 2009 (H1N1) virus infection. Pandemic influenza A 2009 (H1N1) virus testing was performed in each institution. The study was approved by the coordinator local ethics committee and informed consent was obtained from all subjects.

Clinical assessment and follow up {#Sec4}
---------------------------------

Microbiological studies, hospital and intensive care unit (ICU) admission criteria, and treatment decisions were not standardized and were made by attending physicians at each study center. Patients were seen during their hospital stay by one or more of the investigators at each participating hospital, who recorded the clinical data in a standardized, computer-assisted protocol. Data were collected on demographic characteristics, co-morbidities, body mass index (BMI), previous vaccination, clinical signs and symptoms, laboratory analysis, chest X-ray findings, antiviral and antibacterial therapy, concomitant and/or secondary infection, time to clinical stability, and outcomes, including readmissions (\<30 days) and mortality. A long-term follow up visit took place one month after discharge. A senior investigator validated all data.

Definitions {#Sec5}
-----------

*Non-HIV ISP* were considered as those patients with major immunosuppressive status different to HIV infection, such as solid-organ transplant and hematopoietic stem cell transplant (HSCT), active neoplasia, systemic chemotherapy, immunosuppressive therapy, asplenia, or congenital immunodeficiencies. Patients with corticosteroid treatment were considered as those with a dosage of prednisone \>15 mg, or equivalent, during more than 15 days or with bolus. *Neutropenic* patients were considered as those with neutrophil cell count bellow 500/μl. *Obesity* was defined as a BMI ≥ 30 and *morbidly obese* as a BMI ≥40. *Vaccinated patients* included all individuals who had received the *pneumococcal vaccine* in the previous 5 years or the seasonal *influenza vaccine* in the previous year. *Pneumonia* was defined as the presence of a new infiltrate on a chest radiograph for which other causes were excluded and the severity of pneumonia was assessed according to the PSI score \[[@CR10]\] and the CURB-65 score \[[@CR11]\].

*Bacterial co-infection* was considered if bacteria were identified in blood and respiratory samples, or in cases with positive urinary antigen tests for *Streptococcus pneumoniae* and *Legionella pneumophila* serogroup 1. *Complicated influenza* was considered in cases of admission to ICUs, acute respiratory distress syndrome (ARDS), acute coronary event, shock, or death.

*Overall mortality* was defined as death from any cause within 30 days of diagnosis.

Statistical analysis {#Sec6}
--------------------

The results were analyzed using the statistical software package PASW Statistics, version 18.0.1. A descriptive statistical analysis was performed. Continuous variables are expressed as median and range or mean ± standard deviation. The Chi-square or Fisher's exact tests were used for categorical variables and the Mann--Whitney test and Wilcoxon test for continuous variables, when appropriate. Statistical significance was established at α = 0.05. All reported *p*-values are two-tailed.

Results {#Sec7}
=======

A total of 559 patients with pandemic influenza A 2009 (H1N1) were included, of whom 56 (10%) were considered to be immunosuppressed (Fig. [1](#Fig1){ref-type="fig"}). The most common causes of immunosuppression were: solid or hematological malignancies in 19 cases (33.9%), of whom 5 (8.9%) were neutropenic and 3 (5.4%) received an HSCT; solid-organ transplant in 18 cases (32.1%); and corticosteroid therapy in 13 cases (23.2%) (Table [1](#Tab1){ref-type="table"}). Fig. 1Patients with influenza A 2009 (H1N1) infection admitted to the hospital in several Spanish hospitals between April 20, 2009 and November 11, 2009 Table 1Causes of immunosuppression of patients with influenza A 2009 (H1N1) virus infectionSolid-organ transplant recipients, no. (%)18 (32.1%)- Kidney, no.11- Liver, no.4- Heart, no.1- Pancreas, no.1- Kidney--pancreas, no.1Oncohematological patients, no. (%)19 (33.9%)Solid neoplasm receiving chemotherapy, no.12- Breast cancer, no.3- Lung cancer, no.3- Colorectal cancer, no.2- Glioblastoma, no.2- Gonadal tumor, no.1- Osteosarcoma, no.1Hematological malignancies, no.7- Leukemia, no.3- Hematopoietic steam cell transplantation, no.3- Essential thrombocytosis, no.1Corticosteroids continuous therapy patients, no. (%)13 (23.2%)Chronic lung diseases, no.5- Chronic obstructive pulmonary disease, no.4- Cystic fibrosis, no.1Connective tissues diseases, no.4Adrenal insufficiency syndrome, no.2Other pathologies2Other situations6 (10.7%)Asplenic patients3Multiple sclerosis2Combined variable immunodeficiency1

Besides immunosuppression, 98.2% of the ISP had at least one underlying medical condition versus 47.1% of non-ISP. Immunosuppressed patients had more frequent chronic renal and liver insufficiency, while those who were non-ISP were more frequently asthmatic, tobacco smokers, and obese (Table [2](#Tab2){ref-type="table"}). Table 2Demographic characteristics of patients with influenza A 2009 (H1N1) virus infectionVariableISP, *n* (%)Non-ISP, *n* (%)*p*-valueRR (95% CI)Age, years, median (range)46 (17--87)36 (16--83)0.003Male sex36 (64.3)246 (48.9)0.0291.7 (1.05--2.9)Tobacco smoker10 (17.9)160 (32.1)0.0280.4 (0.2--0.9)Alcohol2 (3.6)28 (5.7)\>0.05Underlying conditions55 (98.2)237 (47.1)\<0.00150.3 (7--360.9)- Chronic renal failure11 (19.6)12 (2.4)\<0.0015.7 (3.4--9.4)- Chronic liver insufficiency5 (8.9)16 (3.2)0.0492.5 (1.1--5.6)- Chronic heart disease5 (8.9)34 (6.8)\>0.05- Chronic pulmonary disease11 (19.6)150 (29.8)\>0.05- Chronic obstructive pulmonary disease5 (8.9)39 (7.8)\>0.05- Asthma4 (7.1)98 (19.5)0.0230.3 (0.1--0.9)- Diabetes mellitus8 (14.3)47 (9.3)\>0.05- Obesity3 (5.4)84 (16.7)0.0260.3 (0.1--0.9)Influenza vaccine 08/0915 (33.3)33 (7.6)\<0.0014.4 (2.6--7.7)Influenza vaccine 09/105 (10.2)15 (3.3)0.0342.78 (1.2--6.2)Pneumococcal vaccine6 (13.6)8 (1.9)\<0.0015.18 (2.6--10.1)ISP: immunosuppressed patients; non-ISP: non-immunosuppressed patients

Clinical manifestations in ISP {#Sec8}
------------------------------

The median time from the onset of illness to hospital admission was 2 days (range 1--4). The most common symptoms were cough in 50 cases (89.3%) and fever in 34 (60.7%). Six patients (10.7%) were hypoxemic (SatO~2~ \<90%). Nineteen ISP had pneumonia (33.9%). The severity of pneumonia was assessed at admission, with eight patients classified in the PSI risk groups IV--V (42.1%) and two patients with CURB-65 score \>2 (10.5%). At influenza diagnosis, the laboratory findings in ISP that differed from previous basal values were leukocyte count/μl (7,272.3 ± 465.6 vs. 5,775.1 ± 687.1, *p* = 0.004), lymphocyte count/μl (1,671.1 ± 147.6 vs. 847.2 ± 104.3, *p* \< 0.001), platelet count (208,938 ± 15,072 vs. 169,630 ± 14,599, *p* = 0.005), hematocrit (38.2% ± 0.8% vs. 36.1% ± 0.9%, *p* = 0.002), and natremia (139.4 ± 0.5 meq/l vs. 135.1 ± 0.8 meq/l, *p* \< 0.001).

Immunosuppressed patients had more frequently neutropenia, leukopenia, anemia, and renal insufficiency (serum creatinin \> 1.5 mg/dl). The main clinical manifestations, and radiological and analytical findings are detailed in Table [3](#Tab3){ref-type="table"}. Table 3Clinical, laboratory, and radiological findings of immunosuppressed patients and non-immunosuppressed patients with influenza A 2009 (H1N1) infectionsVariableISP, *n* = 56Non-ISP, *n* = 503*p*-valueRR (95% CI)Days since onset of symptoms, median (range)2 (1--14)3 (0--21)\>0.05Rhinorrhea, no. (%)7 (12.5)110 (21.9)\>0.05Sore throat, no. (%)11 (19.6)145 (28.8)\>0.05Chills, no. (%)11 (19.6)126 (25)\>0.05Cough, no. (%)50 (89.3)453 (90.1)\>0.05Dyspnea, no. (%)20 (35.7)238 (47.3)\>0.05Pleuritic chest pain, no. (%)7 (12.5)84 (16.7)\>0.05Gastrointestinal disorders, no. (%)10 (17.8)124 (24.6)\>0.05Myalgia/arthralgia, no. (%)27 (48.2)297 (59.1)\>0.05Headache, no. (%)18 (32.1)164 (32.7)\>0.05Expectoration, no. (%)27 (48.2)208 (41.3)\>0.05Fever at admission (≥38°C), no. (%)34 (60.7)261 (51.8)\>0.05Hypoxemia (Sat O~2~ \<90), no. (%)6 (10.7)69 (13.7)\>0.05Leukopenia (\<4,000/mm^3^), no. (%)20 (35.7)59 (11.7)\<0.0013.3 (2--5.5)Leukocytosis (\>12,000/mm^3^), no. (%)8 (14.3)66 (13.1)\>0.05Neutropenia (\<500/mm^3^), no. (%)5 (8.9)0 (0)0.00110.9 (8.3--14.1)Lymphopenia (\<1,500/mm^3^ ), no. (%)43 (76.8)406 (80.7)\>0.05Anemia (hematocrit \<36%), no. (%)47 (83.9)110 (21.9)\<0.0012.9 (1.7--4.6)Thrombocytopenia (\<150.10^3^/mm^3^), no. (%)18 (32.1)123 (24.5)\>0.05AST \>40 U/l, no. (%)10 (17.9)88 (17.5)\>0.05ALT \>40 U/l, no. (%)9 (16.1)106 (21.1)\>0.05Hyponatremia \<135 mmol/l, no. (%)15 (26.8)125 (24.8)\>0.05Serum creatine \>1.5 mg/dl, no. (%)16 (28.6)59 (11.7)0.0012.5 (1.5--4.2)LDH \> 350 U/l , no. (%)11 (19.6)115 (22.9)\>0.05Glucose, mg/dl (mean ± SD)120.5 ± 8.5118.7 ± 2.8\>0.05C-reactive protein \>20 mg/l, no. (%)23 (41.1)231 (45.9)\>0.05Pneumonia, no. (%)19 (33.9)203 (40.4)\>0.05- Alveolar opacities, no. (%)17 (89.4)148 (72.9)\>0.05- Multilobar infiltrates, no. (%)10 (52.6)117 (57.6)\>0.05- PSI score, median (range)87 (45--146)46 (4--153)\<0.001- CURB score, median (range)0.5 (0--3)0 (0--3)\>0.05ISP: immunosuppressed patients; non-ISP: non-immunosuppressed patients; AST:alanine aminotransferase; ALT: aspartate aminotransferase

Bacterial co-infection {#Sec9}
----------------------

Bacterial co-infection was more frequent in ISP (17.9% vs. 6.4%, RR 2.7, 95% CI 1.4--4.9, *p* = 0.02). In cases of complicated influenza infection, the proportion of bacterial co-infection was 71.4% in ISP and 12.3% in non-ISP (RR 12.5, 95% CI 2.6--57.3, *p* \< 0.001). The bacteria identified in each group of patients are detailed in Table [4](#Tab4){ref-type="table"}. Immunosuppressed patients were more frequently co-infected with gram-negative bacilli (7.1% vs. 0.6%, RR 17.6, 95% CI 1.6--194.9, *p* = 0.002) and *Staphylococcus aureus* (3.6% vs. 0.2%, RR 11.9, 95% CI 2.7--52.1, *p* = 0.02). Table 4Bacterial co-infections in patients with influenza A 2009 (H1N1) virus infectionMicroorganismsNo. (%)Samples (*n*)Immunosuppressed patients10 (17.9)*Streptococcus pneumoniae*3 (5.4)Sputum (1), antigenuria (2)*Staphylococcus aureus*2 (3.6)Sputum (1), blood: bronchoalveolar lavage (1)*Pseudomonas aeruginosa*2 (3.6)Sputum (2)*Acinetobacter baumannii*1 (1.8)Sputum (1)*Escherichia coli*1 (1.8)Blood (1)*Streptococcus sanguis*1 (1.8)Blood (1)Non-immunosuppressed patients32 (6.4%)*Streptococcus pneumoniae*23 (4.6)Sputum (3), blood (2), antigenuria (16), antigenuria: sputum (2)*Staphylococcus aureus*1 (0.2)Sputum (1)*Pseudomonas aeruginosa*1 (0.2)Sputum (1)*Acinetobacter baumannii*1 (0.2)Blood: bronchoalveolar lavage (1)*Haemophilus influenzae*3 (0.6)Sputum (3)*Moraxella catarrhalis*2 (0.4)Sputum (2)*Stenotrophomonas maltophilia*1 (0.2)Sputum (1)*Haemophilus parainfluenzae*1 (0.2)Blood (1)*Streptococcus pyogenes*1 (0.2)Pleural fluid (1)

Treatment and clinical outcomes in ISP {#Sec10}
--------------------------------------

All patients were treated with oseltamivir at a median of 5 days after the onset of symptoms (range 3--14 days), with a dosage of 75 mg bid in all but one patient (1.8%) that received 150 mg bid. One patient (1.8%) was treated with zanamivir. Forty-four patients (78.5%) received antibiotics, 28 (50%) corticosteroids, and two (3.6%) inotropic vasopressors.

The median duration of fever and cough were 2 days, respectively.

Seven patients (12.5%) had influenza-related complications. Of those, four patients (7.1%) were admitted to the ICU and mechanically ventilated, and four patients presented septic shock (Table [5](#Tab5){ref-type="table"}). Table 5Treatment and clinical outcomes of patients with influenza A 2009 (H1N1) virus infectionCharacteristicsImmunosuppressed patients, *n* = 56Non-immunosuppressed patients, *n* = 503TreatmentAntiviral therapy, no. (%)56 (100)\*463 (92.1)\*- Time since onset of symptoms to antiviral therapy, days, median (range)5 (3--14)5.5 (4--11)- Antiviral therapy within 48 h since onset of symptoms, no. (%)24 (42.9)169 (36.6)Antibacterial therapy, no. (%)44 (78.5)351 (69.8)- Antibacterial therapy within 4 h since hospital admission, no. (%)12 (27.3)90 (25.7)- Duration, days, median (range)9 (1--23)6.5 (5--13)Statins, no. (%)5 (8.9)25 (5.1)Angiotensin-converting enzyme inhibitors, no. (%)4 (7.1)30 (6.1)Inotropic vasopressor, no. (%)2 (3.6)23 (4.6)Corticosteroids \> 300 mg/day, no. (%)3 (5.3)47 (9.3)- Duration in days, median (range)5 (13--14)5.5 (2--15)OutcomeTime to clinical stability, days, median (range)3 (1--21)3 (1--21)Length of hospital stay, days, median (range)2 (1--32)5 (1--98)Complicated influenza infection, no. (%)7 (12.5%)71 (14.1%)Intensive care unit admission, no. (%)4 (7.1%)64 (12.7%)Invasive mechanical ventilation, no. (%)4 (7.1%)46 (9.1%)Mortality, no. (%)4 (7.1%)\*\*9 (1.8%)\*\*\*RR 1.09, 95% CI 1.06--1.1, *p* = 0.01\*RR 4.8, 95% CI 1.5--15.0, *p* = 0.01

Four ISP, all of them with pneumonia died. Mortality was higher in ISP than in non-ISP (7.1% vs. 1.8%, RR 4.8, 95% CI 1.5--15.0; *p* = 0.01).

Risk factors for complicated influenza A 2009 (H1N1) infection were: pneumonia (100% vs. 24.5%, RR 1.5, 95% CI 1.1--2.2, *p* \< 0.01), thrombocytopenia (71.5% vs. 26.5%, RR 5.2, 95% CI 1.1--24.6, *p* = 0.03), bacterial co-infection (71.4% vs. 10.2%, RR 11.5, 95% CI 2.5--51, *p* \< 0.01), and early antiviral therapy (0% vs. 49%, RR 0.8, 95% CI 0.6--0.9, *p* = 0.015). All patients with complicated disease started antiviral therapy later than 3 days after the onset of symptoms. No other factors were associated with complicated influenza in terms of underlying diseases, age or sex, antecedent of vaccination, type of immunosuppression, and clinical findings.

Organ transplant recipients {#Sec11}
---------------------------

Solid-organ transplant recipients received more frequently influenza and pneumococcal vaccine than the rest of the ISP (50% vs. 15.7%, RR 3, 95% CI 1.3--6.8, *p* = 0.007 and 27.8% vs. 2.6%, RR 3.1, 95% CI 1.7--6, *p* = 0.01, respectively) (Table [6](#Tab6){ref-type="table"}). Table 6Characteristics, clinical and laboratory findings, and outcome in different groups of immunosuppressed patientsVariableTransplant organ recipients, *n* = 18Oncohematological patients, *n* = 19Corticosteroids therapy, *n* = 13Age, years, mean ± SD44.3 ± 4.341.8 ± 2.752.3 ± 5.3Male sex, no. (%)15 (83.3)13 (68.4)6 (46.2)Tobacco smoker, no. (%)1 (5.6)6 (31.6)2 (15.4)Alcohol, no. (%)0 (0)2 (10.5)0 (0)Underlying conditions- Chronic renal failure, no. (%)11 (61.1)\*0 (0)0 (0)- Chronic liver insufficiency, no. (%)4 (22.2)0 (0)1 (7.7)- Chronic heart disease, no. (%)2 (11.1)1 (5.3)2 (15.4)- Chronic pulmonary disease, no. (%)3 (16.7)2 (10.5)6 (46.2)\*- Chronic obstructive pulmonary disease, no. (%)1 (5.6)0 (0)4 (30.8)\*- Asthma, no. (%)2 (11.1)1 (5.3)1 (7.7)- Diabetes mellitus, no. (%)5 (27.8)2 (10.5)1 (7.7)Influenza vaccine 08/09, no. (%)9 (50)\*1 (5.3)4 (30.8)Influenza vaccine 09/10, no. (%)3 (16.7)0 (0)1 (7.7)Pneumococcal vaccine, no. (%)5 (27.8)\*0 (0)0 (0)Clinical findings- Days since onset of symptoms, median (range)2 (1--14)2.5 (1--7)3 (1--10)- Rhinorrhea, no. (%)3 (16.7)2 (10.5)2 (15.4)- Sore throat, no. (%)3 (16.7)4 (21.1)2 (15.4)- Chills, no. (%)5 (27.8)2 (10.5)3 (23.1)- Cough, no. (%)15 (83.3)18 (94.7)11 (84.6)- Dyspnea, no. (%)5 (27.8)5 (26.3)8 (61.5)- Pleuritic chest pain, no. (%)1 (5.6)3 (15.8)1 (7.7)- Gastrointestinal disorders, no. (%)5 (27.7)3 (15.7)0 (0)- Myalgia/arthralgia, no. (%)8 (44.4)11 (57.9)4 (30.8)- Headache, no. (%)8 (44.4)6 (31.6)4 (30.8)- Expectoration, no. (%)1 (5.6)0 (0)0 (0)Laboratory findingsLeukopenia (\<4,000/mm^3^), no. (%)5 (27.7)14 (73.7)\*1 (7.7)Leukocytosis (\>12,000/mm^3^), no. (%)1 (5.6)1 (5.3)4 (30.8)Neutropenia (\<500/mm^3^), no. (%)0 (0)5 (26.3)\*0 (0)Lymphopenia (\<1,500/mm^3^), no. (%)17 (94.4)\*16 (84.2)7 (53.8)Anemia (Hematocrit \<36%), no. (%)10 (55.6)12 (63.2)5 (38.5)Thrombocytopenia (\<150.10^3^/mm^3^), no. (%)7 (38.9)9 (47.4)2 (15.4)AST \>40 U/l, no. (%)4 (22.2)4 (21.1)1 (7.7)ALT \>40 U/l, no. (%)1 (5.6)6 (31.6)\*1 (7.7)Hyponatremia \<135 mmol/l, no. (%)6 (33.3)5 (26.3)3 (23.1)Serum creatine \>1.5 mg/dl, no. (%)12 (66.7)\*1 (5.3)2 (15.4)LDH \> 350 U/l, no. (%)1 (5.6)8 (42.1)1 (7.7)C-reactive protein \>20 mg/l, no. (%)6 (33.3)8 (42.1)7 (53.8)Radiological findingsPneumonia, no. (%)5 (27.8)6 (31.6)4 (30.8)- Alveolar opacities, no. (%)5 (100)5 (83.3)3 (75)- Multilobar infiltrates, no. (%)3 (16.7)4 (21.1)2 (15.4)- PSI score, median (range)103 (71--131)89 (48--146)57.5 (47--146)- CURB score, median (range)1 (0--3)2 (0--2)0 (0--3)Clinical outcomesDays to clinical stability, median(range)2 (1--14)2.5 (1--7)3 (1--10)Related complications, no. (%)1 (5.6)3 (15.8)3 (23.1)Intensive care unit admission, no. (%)1 (5.6)0 (0)3 (23.1)Septic shock, no. (%)0 (0)2 (10.5)0 (0)Hospital stay, days, median (range)5 (2--28)6 (1--25)7 (3--32)Death, no. (%)1 (5.6)3 (15.8)0 (0)\**p* \< 0.05LDH: lactate dehydrogenase

Influenza symptoms and signs did not differ from those of other ISP, with the exception of lymphopenia (94.4% vs. 68.4% RR 2.5, 95% CI 1.8--3.5, *p* \< 0.001). Bacterial co-infection was detected in three patients (16.6%): *S. aureus* was isolated in two cases and *Pseudomonas aeruginosa* in one case.

Five patients had pneumonia (27.8%), with a median CURB-65 score of 1 (range 0--3). One patient with an *S. aureus* bacteremia died (5.5%) three days after transplantation.

Oncohematological patients {#Sec12}
--------------------------

Oncohematological patients had more frequent laboratory disturbances, such as leukopenia (73.7% vs. 16.2%, RR 5.04, 95% CI 2.1--11.9, *p* \< 0.001), neutropenia (26.3% vs. 0%, RR 3.64, 95% CI 2.3--5.7, *p* = 0.003), hypertransaminasemia (31.5% vs. 16.2%, RR 2.41, 95% CI 1.2--4.4, *p* = 0.04), and increased lactate dehydrogenase levels (42.1% vs. 5.4%, RR 7.8, 95% CI 1.8--33.1, *p* = 0.001) than the rest of the ISP (Table [6](#Tab6){ref-type="table"}).

Six patients (31.6%) had pneumonia. Bacterial co-infection was present in four oncohematological patients (21.1%): *S. pneumoniae* in two cases, *Escherichia coli* in one patient, and *Acinetobacter baumannii* in another case. In 40% of neutropenic patients, a bacterial co-infection was detected. Three patients who received chemotherapy due to solid neoplasm, two of whom were neutropenic, died (15.8%). Mortality among neutropenic patients was higher than in non-neutropenic ISP (40% vs. 3.9%, RR 10.2, 95% CI 1.8--57.0, *p* = 0.03).

Corticosteroids continuous therapy patients {#Sec13}
-------------------------------------------

Nine of the thirteen patients with corticosteroid therapy had dyspnea (69.2%). Laboratory findings revealed fewer abnormalities than the rest of the ISP (Table [6](#Tab6){ref-type="table"}). Bacterial co-infection was detected in three patients (23.1%): *Streptococcus sanguis*, *P. aeruginosa*, and *S. pneumoniae*. Four patients (30.8%) had pneumonia and three (23.1%) had influenza-related complications, all of them requiring ICU admission and mechanical ventilation. None of the patients died.

Discussion {#Sec14}
==========

Pandemic influenza A 2009 (H1N1) virus infection in ISP causes a more severe disease than in non-ISP. Globally, mortality is higher in ISP, but the severity of the illness depends on the type of immunosuppression. The only modifiable risk factor of complicated influenza infection was early instauration of antiviral therapy.

Seasonal influenza is a common cause of infection each winter in ISP, with a high rate of short- and long-term related complications, including viral pneumonia and secondary bacterial pneumonia \[[@CR3], [@CR8], [@CR9]\].

Clinical features of pandemic influenza in the general population are similar to that of seasonal influenza, with a higher rate of primary viral pneumonia and gastrointestinal and neurological symptoms, especially in young children \[[@CR7], [@CR12], [@CR13]\]. Peck et al. \[[@CR14]\], in a study of seasonal influenza in HSCT recipients, observed that most patients presented upper respiratory symptoms with few systemic symptoms, such as fever or myalgia. Studies carried out in the transplant setting showed diverse results, with a high proportion of patients having low respiratory and systemic symptoms \[[@CR1], [@CR9]\]. The clinical findings of pandemic influenza A 2009 (H1N1) infection in different groups of ISP have been reported. A recent study reported that patients with cancer had fever and cough in almost all cases, with lower respiratory tract involvement occurring in 27% of them \[[@CR15]\]. George et al. \[[@CR16]\] reported 13 cases of influenza A 2009 (H1N1) infection occurring in HSCT recipients, with lower respiratory tract disease in 38.7% of the patients. In solid-organ transplant recipients, a retrospective study of 154 adults with influenza A showed similar clinical findings, with one-third of the patients having pneumonia \[[@CR17]\]. To our knowledge, this is the first study that directly compares the clinical manifestation according to the presence of immunosuppression, and we observed that, although the clinical symptoms and signs were very similar, laboratory disturbances such as neutropenia, leukopenia, anemia, and renal insufficiency were more frequent in the ISP. Some of these, such as renal insufficiency or anemia, were present before the influenza episode and are probably related to the underlying disease and therapy of the ISP, while others, such as lymphopenia, thrombocytopenia, or anemia, significantly worsen after influenza infection, possibly due to an effect of the viral infection in this type of patient.

In ISP, respiratory viruses lead to prolonged clinical courses, with the risk of progression of the infection to the lower respiratory tract and increased mortality when compared to the immunocompetent population \[[@CR2], [@CR18]\]. The severity of seasonal influenza in ISP is variable according to the different studies published. Ljungman et al. \[[@CR1]\], in a series of ISP with seasonal influenza, observed that most of the cases were mild. Schnell et al. \[[@CR3]\], in a retrospective study of hospitalized ISP with seasonal influenza, reported that one-half of the patients had a pneumonia and one-third of patients were admitted to the ICU, with a 10% mortality rate. Other studies carried out in ISP with seasonal influenza report a mortality rate ranging from 0 to 25% \[[@CR1], [@CR8], [@CR19]\]. Severe influenza A H1N1 infection has been associated with IgG~2~ deficiency \[[@CR20]\]. In the present study, although there were no differences in some outcome variables, such as admission to ICUs, progression to lower respiratory tract or septic shock, the risk of death during the influenza episode was four times higher in the ISP. However, the severity and outcome of the infection deferred according to the degree of immunosuppression: patients with corticosteroid therapy presented less frequently analytical disturbances and complicated diseases with a better outcome, while oncohematological patients had higher mortality, especially those profoundly neutropenic.

The impact of corticosteroids on influenza severity and outcome are conflicting, since there are no randomized trials assessing this effect. High-dose steroids may prolong viral shedding in HSCT recipients \[[@CR8], [@CR21]\] and increase the risk of lower respiratory tract diseases in pediatric cancer patients. But in other studies, it has been suggested that progression to lower respiratory tract diseases may be reduced or not affected \[[@CR8], [@CR21]\]. In our experience, patients previously treated with corticosteroids showed a better outcome than other ISP and similar to that of non-ISP.

Although initially a low rate of bacterial co-infection was reported in cases of pandemic influenza A (H1N1) with severe pneumonia \[[@CR6], [@CR7]\], later studies showed that bacterial co-infection could be found in 28--55% of fatal cases \[[@CR22], [@CR23]\]. In the present study, the proportion of patients co-infected was higher in ISP, and this was especially important in those with complicated diseases, where three-quarters of cases presented a bacterial co-infection. The isolated bacteria were also different from non-ISP, with a higher proportion of gram-negative bacilli and *S. aureus* infections. Co-infection by these microorganisms is probably related to the close contact of these patients with healthcare facilities. The high frequency of co-infection in severe cases and the presence of "non-strict" community-acquired respiratory pathogens would determine, according to the local epidemiology, the need for using broad-spectrum antibacterial agents in severe cases of influenza A 2009 (H1N1) in ISP.

Delayed hospital admission and antiviral therapy have been associated with an unfavorable outcome in the general population and in solid-organ transplant recipients \[[@CR17], [@CR24], [@CR25]\]. In the present study, all patients with complicated diseases started therapy beyond the first 48 h of symptoms. Indeed, this was the only modifiable risk factor of complicated influenza A 2009 (H1N1) infection in this population. Although the proportion of patients receiving antiviral therapy was much higher than that described in series of seasonal influenza \[[@CR1], [@CR9]\], an effort should be made to decrease the time of onset of antiviral therapy. For this reason, during epidemiological risk periods, ISP should be screened for symptoms and early influenza diagnosis and therapy should be considered in those cases with compatible syndromes or pneumonia.

Our study has several limitations. First, serological studies of atypical pathogens of community-acquired pneumonia could not be systematically done, and, therefore, co-infection by atypical microorganisms could not be ruled out. Second, susceptibility to oseltamivir was not performed, and, therefore, we cannot determine if oseltamivir resistance was associated with complicated diseases. Finally, as the outcome of influenza A 2009 (H1N1) infection was not previously known, it is possible that the decision of hospitalizing ISP was not only related to the severity of the underlying disease and to the degree of complications detected, but also to general caution regarding the management of these patients, and milder cases than in non-ISP patients would have been hospitalized.

In summary, influenza A 2009 (H1N1) virus infection in ISP causes a disease with clinical symptoms similar to those of non-ISP, but with higher related mortality, especially in neutropenic patients. Bacterial co-infection is frequent in complicated cases, with a high rate of gram-negative bacilli. Clinicians should have a high index of suspicion in pandemic or epidemic periods in order to initiate antiviral therapy early.
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